Company Overview - Enanta Pharmaceuticals (ENTA) shares increased by 5.6% to close at $10.94, following a period of 19.6% loss over the past four weeks, indicating a significant recovery in trading volume [1] - The company is a member of the Zacks Medical - Drugs industry, which includes other companies like BioCryst Pharmaceuticals (BCRX) [4] Recent Developments - Enanta Pharmaceuticals announced positive top-line data from a phase IIa human challenge study for its candidate EDP-323, showing significant reductions in viral load and clinical symptoms in healthy adults infected with respiratory syncytial virus [2] - The consensus EPS estimate for Enanta's upcoming quarterly report has been revised 5.3% higher over the last 30 days, suggesting a positive trend that may lead to further price appreciation [4] Financial Expectations - The company is expected to report a quarterly loss of $1.16 per share, reflecting a year-over-year change of +12.8%, with revenues projected at $18.73 million, down 1.1% from the previous year [3] - BioCryst Pharmaceuticals, a peer in the industry, has an unchanged EPS estimate of -$0.07, which represents a 63.2% improvement from the prior year [5]

Company Overview - Enanta Pharmaceuticals (ENTA) shares increased by 6.7% in the last trading session, closing at $16, with notable trading volume compared to typical sessions [1] - The stock has gained 11.6% over the past four weeks [1] Industry Context - Enanta Pharmaceuticals is part of the Zacks Medical - Drugs industry, where another stock, Ardelyx (ARDX), rose by 1.2% to $5.89 but has seen a decline of 10.3% over the past month [2] Financial Expectations - Enanta Pharmaceuticals is expected to report a quarterly loss of $1.49 per share, reflecting a year-over-year change of +19.9% [3] - Revenue for the upcoming report is anticipated to be $17.3 million, which is an 8.4% decrease from the same quarter last year [3] Product Development - The company's lead candidate, zelicapavir, is an oral N-protein inhibitor currently being evaluated in two mid-stage studies for treating respiratory syncytial virus (RSV) in both pediatric and adult patients [4] - Enanta also has a portfolio of small-molecule drugs targeting viral infections, contributing to positive sentiment around the stock [4] Earnings Estimate Trends - The consensus EPS estimate for Enanta Pharmaceuticals has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [6] - In contrast, Ardelyx's consensus EPS estimate has increased by 8.8% over the past month to -$0.10, representing a 25% decline compared to the previous year [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, par value $0.0 ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $17.1 million, a decrease from $17.8 million in Q2 2023, primarily due to lower royalty rates [43][18] - Net loss for the quarter was $31.2 million, or a loss of $1.47 per diluted share, compared to a net loss of $37.7 million, or a loss of $1.79 per diluted share in the same period last year [20] - Research and development expenses decreased to $35.6 million from $43.5 million year-over-year, attributed to reduced costs associated with the COVID-19 program [44][19] - General and administrative expenses increased to $14.2 million from $13.8 million, mainly due to legal expenses related to a patent infringement lawsuit [45] Business Line Data and Key Metrics Changes - The RSV pipeline includes two main candidates: zelicapavir and EDP-323, with ongoing Phase 2 studies aimed at demonstrating safety and efficacy [5][37] - The company is also advancing its immunology program targeting chronic spontaneous urticaria (CSU), with plans to select a clinical candidate by Q4 2024 [41][16] Market Data and Key Metrics Changes - The company reported ongoing royalties from AbbVie's MAVYRET, with 54.5% of royalties being paid to OMERS due to a royalty sale transaction [18] - The company expects its current cash and marketable securities, along with retained royalties, to be sufficient to meet cash requirements through Q3 2027 [21] Company Strategy and Development Direction - Enanta is focused on advancing its virology and immunology pipeline to address high unmet medical needs, particularly in developing oral therapeutics for RSV and CSU [4][15] - The company aims to leverage its expertise in small-molecule drugs to develop best-in-disease therapies for CSU and is exploring additional immunology targets [15][41] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of developing effective treatments for RSV, noting the limitations of current pediatric monoclonal antibodies [10][4] - The company anticipates reporting data from ongoing studies in the second half of 2024, which will inform future clinical development strategies [16][62] Other Important Information - The company welcomed a new Chief Legal Officer, Matthew Kowalsky, who brings over 20 years of experience in the life sciences industry [42] - Enanta is updating its expense guidance, expecting R&D expenses to be between $125 million and $145 million for the fiscal year [46] Q&A Session Summary Question: What will you be looking at in terms of data to inform your design for Phase 3? - Management indicated that they will focus on safety and virology endpoints, with a need for clinically meaningful data to justify moving to Phase 3 [23][24] Question: Can you discuss your strategic plans for the immunology program? - Management stated they are exploring multiple approaches and are looking to broaden beyond the current KIT program [27][28] Question: How close are you to completing enrollment for the RSVPED study? - Management confirmed they are in the final stages of enrollment for the youngest age cohort and are actively recruiting [62] Question: What are your expectations for the EDP-323 challenge study? - Management expressed hope for strong data, aiming to replicate the best-in-class results seen with zelicapavir [60][64] Question: How do you plan to position your oral KIT inhibitor against other therapies? - Management emphasized the goal of achieving a potent and selective oral agent with a good safety profile, aiming for best-in-class status [91][92]

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -16.67%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.18 per share when it actually produced a loss of $1.58, delivering a surprise of -33.90%.Over the last four quarters, t ...

Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET WATERTOWN, Mass., May 6, 2024 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. "At Enanta, we are committed to advancing the first antiviral treatment for RSV, ...

Financial Data and Key Metrics Changes - For the fiscal first quarter ended December 31, 2023, total revenue was $18 million, down from $23.6 million in the same period in 2022 [18] - Research and development expenses decreased to $36.4 million from $40.9 million year-over-year, primarily due to reduced costs associated with the COVID-19 program [20] - Net loss for the quarter was $33.4 million, or a loss of $1.58 per diluted common share, compared to a net loss of $29 million, or a loss of $1.39 per diluted common share for the same period in 2022 [21] - The company ended the quarter with approximately $337 million in cash and marketable securities [21] Business Line Data and Key Metrics Changes - The company is focused on developing treatments for RSV, with two key candidates: zelicapavir and EDP-323, both of which have fast-track designation from the FDA [7][10] - The RSVPEDs study is designed to demonstrate improved virology metrics for zelicapavir, while the RSVHR study aims to show clinically meaningful improvement in symptom resolution [10][34] Market Data and Key Metrics Changes - The current rate of adult RSV vaccine adoption is estimated at only 11% of the eligible population, indicating a significant unmet need in the market [30] - The company believes there is a $1 billion market opportunity for RSV treatments, particularly given the lack of established therapeutics in this area [66] Company Strategy and Development Direction - The company aims to advance its programs in both virology and immunology, focusing on small molecule treatments for high unmet medical needs [29] - The strategy includes leveraging drug discovery capabilities to bolster the pipeline for near and long-term value creation [29] - The company plans to announce a second immunology program in 2024, targeting chronic spontaneous urticaria (CSU) [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of their RSV portfolio, noting the absence of approved drugs for the unmet need [26] - The company anticipates reporting data from the RSVPEDs Phase 2 study in the third quarter of 2024 and aims to identify a clinical candidate for the CSU program this year [16][39] - Management highlighted the importance of understanding the competitive landscape for COVID treatments and how it may impact strategic decisions [57] Other Important Information - General and administrative expenses for the quarter increased to $16.5 million from $12.7 million in the same period in 2022, primarily due to higher stock compensation and legal expenses [62] - The company expects its current cash and marketable securities will be sufficient to meet anticipated cash requirements through fiscal 2027 [63] Q&A Session Summary Question: What is the expected outcome for the RSVPEDs study? - Management indicated that they are primarily looking for virology endpoints and numerical trends that would support moving into a Phase 3 study [76] Question: How does the company view the competitive landscape for COVID treatments? - Management noted that the recent developments simplify the COVID landscape and will help clarify future funding decisions [78] Question: What are the expectations for the new immunology program? - The company is targeting good markets with high unmet medical needs and plans to announce the program later this year [116] Question: What is the financial guidance for operating expenses? - The company confirmed that the operating expense guidance remains at $100 million to $120 million for R&D and $45 million to $50 million for G&A [118]

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.90%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.11 per share when it actually produced a loss of $1.33, delivering a surprise of 36.97%.Over the last four quarters, th ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023. “In 2024, Enanta began a year which will be marked by execution and value creation across the company. We are preparing for multiple catalysts across our pipeline in 2024, starting with RSV, where we anticipate reporting topline data f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) | Title of each class | Trading Symbol(s) | Name of each exchange on which regis ...